These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 10052897

  • 1. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM, Szekely A, Warnock DW.
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [Abstract] [Full Text] [Related]

  • 2. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A.
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [Abstract] [Full Text] [Related]

  • 3. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group.
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.
    Johnson EM, Szekely A, Warnock DW.
    Antimicrob Agents Chemother; 1999 May; 43(5):1260-3. PubMed ID: 10223947
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.
    Espinel-Ingroff A, Boyle K, Sheehan DJ.
    Mycopathologia; 2001 May; 150(3):101-15. PubMed ID: 11469757
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
    Morace G, Drago M, Scaltrito MM, Conti S, Fanti F, Polonelli L, GISIA Participants Group.
    J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.
    Espinel-Ingroff A.
    J Clin Microbiol; 1998 Jan; 36(1):198-202. PubMed ID: 9431946
    [Abstract] [Full Text] [Related]

  • 11. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.
    Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR.
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1734-6. PubMed ID: 10817743
    [Abstract] [Full Text] [Related]

  • 12. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
    Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH.
    J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
    [Abstract] [Full Text] [Related]

  • 13. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.
    McGinnis MR, Nordoff N, Li RK, Pasarell L, Warnock DW.
    Med Mycol; 2001 Aug; 39(4):369-71. PubMed ID: 11556767
    [Abstract] [Full Text] [Related]

  • 14. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, Martínez-Suárez JV, Monzón A.
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE, Wiederhold NP, Klepser ME.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [Abstract] [Full Text] [Related]

  • 18. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
    Oakley KL, Moore CB, Denning DW.
    J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
    [Abstract] [Full Text] [Related]

  • 19. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
    Radford SA, Johnson EM, Warnock DW.
    Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501
    [Abstract] [Full Text] [Related]

  • 20. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A.
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.